Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AVR 118

Drug Profile

AVR 118

Alternative Names: AVR-118; AVR123; OHR-118; OHR/AVR 118; Peptide R; Product R; Reticulose; Substance R

Latest Information Update: 10 Nov 2016

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Advanced Viral Research
  • Developer Advanced Viral Research; McGill University; Ohr Pharmaceutical
  • Class Antineoplastics; Antirheumatics; Antivirals; Peptide nucleic acids
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Anorexia; Cachexia; Cancer; Haematological malignancies; HIV infections; Human papillomavirus infections; Multiple sclerosis; Rheumatoid arthritis; Type 2 diabetes mellitus; Wounds

Most Recent Events

  • 10 Nov 2016 Discontinued - Phase-II for Anorexia (In the elderly, In adults) in Canada before November 2016 (SC)
  • 21 Mar 2013 Efficacy and adverse events data from a phase II trial in Cachexia released by Ohr Pharmaceuticals
  • 21 Mar 2013 Ohr Pharmaceuticals completes a phase II trial in Cachexia in Canada (NCT01206335)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top